SCYNEXIS (SCYX) Competitors $1.20 -0.06 (-4.76%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SCYX vs. ETTX, ADAP, SCPH, DRUG, GALT, GOSS, DMAC, MDWD, SGMT, and NBTXShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Entasis Therapeutics (ETTX), Adaptimmune Therapeutics (ADAP), scPharmaceuticals (SCPH), Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), Gossamer Bio (GOSS), DiaMedica Therapeutics (DMAC), MediWound (MDWD), Sagimet Biosciences (SGMT), and Nanobiotix (NBTX). These companies are all part of the "medical" sector. SCYNEXIS vs. Entasis Therapeutics Adaptimmune Therapeutics scPharmaceuticals Bright Minds Biosciences Galectin Therapeutics Gossamer Bio DiaMedica Therapeutics MediWound Sagimet Biosciences Nanobiotix SCYNEXIS (NASDAQ:SCYX) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Which has higher valuation & earnings, SCYX or ETTX? SCYNEXIS has higher revenue and earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$140.14M0.32$67.04M-$0.74-1.62Entasis Therapeutics$7M14.97-$47.14M-$1.12-1.96 Which has more risk & volatility, SCYX or ETTX? SCYNEXIS has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Entasis Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Does the media prefer SCYX or ETTX? In the previous week, SCYNEXIS had 6 more articles in the media than Entasis Therapeutics. MarketBeat recorded 6 mentions for SCYNEXIS and 0 mentions for Entasis Therapeutics. SCYNEXIS's average media sentiment score of 1.06 beat Entasis Therapeutics' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Positive Entasis Therapeutics Neutral Is SCYX or ETTX more profitable? Entasis Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. SCYNEXIS's return on equity of -66.21% beat Entasis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-425.41% -66.21% -38.84% Entasis Therapeutics N/A -145.48%-103.75% Does the MarketBeat Community favor SCYX or ETTX? SCYNEXIS received 409 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote. CompanyUnderperformOutperformSCYNEXISOutperform Votes50570.04% Underperform Votes21629.96% Entasis TherapeuticsOutperform Votes9664.86% Underperform Votes5235.14% Do analysts rate SCYX or ETTX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Entasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in SCYX or ETTX? 54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 6.9% of Entasis Therapeutics shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by company insiders. Comparatively, 6.5% of Entasis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummarySCYNEXIS beats Entasis Therapeutics on 14 of the 17 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.54M$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-1.624.4062.6013.00Price / Sales0.32377.651,277.9088.72Price / Cash0.6351.2139.7935.27Price / Book0.789.636.455.92Net Income$67.04M$154.43M$119.73M$225.73M7 Day Performance-8.40%-9.46%-5.13%-1.34%1 Month Performance-20.53%-7.27%-2.71%1.15%1 Year Performance-25.93%28.13%31.08%24.02% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS2.4281 of 5 stars$1.20-4.8%N/A-24.1%$45.54M$140.14M-1.6260Positive NewsETTXEntasis TherapeuticsN/A$2.19flatN/A+0.0%$104.80M$7M-1.9651ADAPAdaptimmune Therapeutics2.1677 of 5 stars$0.77-2.9%N/A+17.3%$197.05M$60.28M-2.20449Analyst ForecastAnalyst RevisionNews CoverageSCPHscPharmaceuticals4.013 of 5 stars$3.90-0.8%N/A-31.1%$195.11M$24.05M-2.5030Analyst ForecastAnalyst RevisionNews CoverageDRUGBright Minds Biosciences2.3947 of 5 stars$42.41+6.9%N/A+2,994.5%$187.88MN/A-62.37N/AShort Interest ↓Positive NewsGap DownGALTGalectin Therapeutics1.8669 of 5 stars$3.00+1.4%N/A+46.6%$186.84MN/A-3.809Analyst DowngradeAnalyst RevisionNews CoveragePositive NewsGOSSGossamer Bio4.3817 of 5 stars$0.81-4.1%N/A-10.3%$184.25MN/A-2.54180Short Interest ↓Analyst RevisionNews CoverageDMACDiaMedica Therapeutics2.2154 of 5 stars$4.32+0.2%N/A+68.5%$184.24MN/A-8.1520Analyst ForecastNews CoverageMDWDMediWound2.0214 of 5 stars$16.83-0.5%N/A+93.2%$181.60M$18.69M-7.7980Positive NewsSGMTSagimet Biosciences2.1282 of 5 stars$5.92-0.3%N/A+103.0%$181.57M$2M0.008Analyst ForecastNews CoverageGap DownNBTXNanobiotix2.3844 of 5 stars$3.83-5.0%N/A-34.5%$180.51M$39.18M0.00100News Coverage Related Companies and Tools Related Companies ETTX Alternatives ADAP Alternatives SCPH Alternatives DRUG Alternatives GALT Alternatives GOSS Alternatives DMAC Alternatives MDWD Alternatives SGMT Alternatives NBTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCYX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.